Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphic Holding Inc (NQ: MORF )

29.80 +1.09 (+3.78%)
Streaming Delayed Price Updated: 9:40 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Morphic Holding Inc

< Previous 1 2 Next >
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
From Morphic Therapeutic
Via GlobeNewswire
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 7/17
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) is a Stock Spotlight on 6/5
Via Investor Brand Network
MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc.  (NASDAQ:MORF)
From Abraham, Fruchter & Twersky, LLP
Via GlobeNewswire
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Experienced Clinical Development Leader with Deep Experience in Immunology and Inflammatory Diseases 
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Participate in March Investor Conferences
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
From Morphic Therapeutic
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Morphic Holding, Inc. (MORF) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Robbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of Investors
From Robbins LLP
Via Business Wire
Morphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of Investors
From Robbins LLP
Via Business Wire
Morphic to Present at November Investor Conferences
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
NASDAQ: MORF Investor Notice: Investigation over Possible Securities Laws Violations by Morphic Holding, Inc.
San Diego, CA -- (SBWIRE) -- 11/01/2023 -- Morphic Holding, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Morphic Holding Investigation: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Investigation
From Johnson Fistel, LLP
Via Business Wire
Morphic Holding SHAREHOLDER ALERT: Johnson Fistel Encourages Morphic Holding Shareholders with Losses to Contact the Firm Regarding Investigation
From Johnson Fistel, LLP
Via Business Wire
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
From Morphic Therapeutic
Via GlobeNewswire
MORF INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Morphic Holding, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Morphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at the Jefferies Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition- 
From Morphic Therapeutic
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.